David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Thursday, June 18, 2015

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate endpoint.

Focus on Classical Hematology (Volume 5, Issue 12.1)

October 2019, Volume 5, Issue 12

September 2019, Volume 5, Issue 11

August 2019, Volume 5, Issue 10

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

Recent Articles

U.K. Labour Party Plans to Regulate Pharmaceutical Market, Lower Drug Prices

Federal Watchdog Report Shows NIH Must Better Protect U.S. Research From Foreign Influence

23andMe Is Building a Clinical Trial Recruitment Business

U.S. Political Tensions Rise as Pelosi and Grassley Release Drug Pricing Bills

FDA Issues Guidelines for Regulating Health AI

Current Issue

October 2019, Volume 5, Issue 12

Meeting Coverage

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Editor`s Corner

Fathers (and Mothers) of Hematology

Our Identity Crisis